Identifying treatment response to antihypertensives in patients with obesity-related hypertension

Ilse M. Schrover, Jannick A.N. Dorresteijn, Jodine E. Smits, A. H.Jan Danser, Frank L.J. Visseren, Wilko Spiering*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)

Abstract

Background: In patients with obesity-related hypertension (ORH), reaction to antihypertensive medication is likely influenced by patientcharacteristics. Methods: Effects of aliskiren, moxonidine and hydrochlorothiazide on 24-h blood pressure (BP) were compared to placebo. Linear mixed effect models were used to analyze the effect of patient characteristics on BP levels and treatment response. Results: Systolic BP response to aliskiren was higher in patients with a BMI > 30.7 kg/m2 compared to patients with a BMI ≤ 30.7 kg/m2 (-21 mmHg versus -4 mmHg). In patients with a hsCRP > 1.8 mg/L the systolic BP response to aliskiren was higher than in patients with a low hsCRP (-15 mmHg versus -7 mmHg). Hydrochlorothiazide (HCTZ) treatment effect on systolic BP was -13 mmHg when heart rate > 71 beats/min compared to -3 mmHg when heart rate was ≤ 71 beats/min. Conclusion: In patients with ORH, BP response to aliskiren is positively related to BMI and hsCRP. Systolic BP response to HCTZ is positively related to heart rate and negatively to renin levels. Trial registration: NCT01138423. Registered June 4th, 2010.

Original languageEnglish
Article number20
JournalClinical Hypertension
Volume23
Issue number1
DOIs
Publication statusPublished - 24 Oct 2017

Bibliographical note

Publisher Copyright: © 2017 The Author(s).

Fingerprint

Dive into the research topics of 'Identifying treatment response to antihypertensives in patients with obesity-related hypertension'. Together they form a unique fingerprint.

Cite this